Page 186 - Read Online

Cui et al. Diagnosis and treatment of meningeal carcinomatosis

107. Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a 116. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R,
durable (>15 months) complete response in an ALK-positive non- Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P,
small cell lung cancer patient who progressed on crizotinib with Gisselbrecht C. CHOP chemotherapy plus rituximab compared with
diffuse leptomeningeal carcinomatosis. Oncologist 2015;20:224-6. CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
108. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, N Engl J Med 2002;346:235-42.
Brastianos PK, Chi AS, Shaw AT. Alectinib salvages CNS relapses in 117. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa
ALK-positive lung cancer patients previously treated with crizotinib S, Damon L, Prados M, McDermott M, O’Brien J, Haqq C, Shuman
and ceritinib. J Thorac Oncol 2015;10:232-6. M. Phase I study of intraventricular administration of rituximab in
109. Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate patients with recurrent CNS and intraocular lymphoma. J Clin Oncol
use for treating carcinomatous meningitis in an ALK translocated non- 2007;25:1350-6.
small-cell lung cancer. J Thorac Oncol 2014;9:e62-3. 118. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert
110. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol A. Intraventricular treatment of relapsed central nervous system
2000;18:2349-51. lymphoma with the anti-CD20 antibody rituximab. Haematologica
111. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. 2004;89:753-4.
Intrathecal trastuzumab and thiotepa for leptomeningeal spread of 119. Floudas CS, Chandra AB, Xu Y. Vemurafenib in leptomeningeal
breast cancer. Ann Oncol 2009;20:792-5. carcinomatosis from melanoma: a case report of near-complete
112. Kordbacheh T, Law WY, Smith IE. Sanctuary site leptomeningeal response and prolonged survival. Melanoma Res 2016;26:312-5.
metastases in HER-2 positive breast cancer: a review in the era of 120. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL.
trastuzumab. Breast 2016;26:54-8. Induction of systemic TH1-like innate immunity in normal volunteers
113. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de following subcutaneous but not intravenous administration of CPG
Azambuja E, Dimopoulos MA, Preusser M. Intrathecal administration 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J
of trastuzumab for the treatment of meningeal carcinomatosis in Immunother 2004;27:460-71.
HER2-positive metastatic breast cancer: a systematic review and 121. Ursu R, Taillibert S, Banissi C, Vicaut E, Bailon O, Le Rhun E,
pooled analysis. Breast Cancer Res Treat 2013;139:13-22. Guillamo JS, Psimaras D, Tibi A, Sacko A, Marantidou A, Belin
114. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page C, Carpentier AF. Immunotherapy with CpG-ODN in neoplastic
M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, meningitis: a phase I trial. Cancer Sci 2015;106:1212-8.
Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, 122. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A,
Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, Puybasset
TM, Lackey K. The characterization of novel, dual ErbB-2/EGFR, L, Van Effenterre R, Delattre JY, Carpentier AF. Phase 1 trial of a CpG
tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro
2001;61:7196-203. Oncol 2006;8:60-6.
115. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski 123. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M,
T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Meng Y, Richard M, Parizot C, Laigle-Donadey F, Gorochov G,
Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Psimaras D, Sanson M, Tibi A, Chinot O, Carpentier AF. Intracerebral
Cameron D. Lapatinib plus capecitabine for HER2-positive advanced administration of CpG oligonucleotide for patients with recurrent
breast cancer. N Engl J Med 2006;355:2733-43. glioblastoma: a phase II study. Neuro Oncol 2010;12:401-8.

178 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ September 18, 2017